
Aspira Women's Health Inc.
93
Recent news coverage includes financial results and program updates from various companies in the healthcare and pharmaceutical sectors, but no direct recent news specific to Aspira Women's Health Inc. was reported after November 2025.
- Aspira announced third quarter 2025 financial results and provided a business update in November 2025 [N1].
- The company won a laboratory service contract with the University of Texas Medical Branch at Galveston in October 2025 [N1].
- Aspira's common stock was welcomed to OTCQX in October 2025 following delisting from Nasdaq [N1].
- The company announced an equity capital infusion of $3.06 million via private placement and warrant exercise in September 2025 [N1].
- Aspira appointed a new Chief Financial Officer in September 2025 [N1].
- The company announced a partnership with Dorsata to offer access to over 300 women's health practices and 1.5 million new patients in June 2025 [N1].
- Aspira provided updates on its ARPA-H Sprint Program partnership to advance women's health in June 2025 [N1].
- The company reached another ARPA-H milestone and became eligible to receive an additional $1.5 million in May 2025 [N1].
Aspira Women's Health Inc. develops and commercializes diagnostic tests that combine multiple biomarkers and AI algorithms to aid in the diagnosis and monitoring of gynecologic diseases. Its flagship products include the Ova1Plus workflow and OvaWatch test, which assess ovarian cancer risk in women with adnexal masses. The company operates Aspira Labs, a CLIA-certified laboratory in Texas, and distributes tests through direct sales and partnerships with major laboratories. Aspira is advancing development of ENDOinform, a non-invasive test for endometriosis, supported by clinical studies and collaborations. The company has FDA regulatory clearances for its tests and is engaged in efforts to expand market access, including Medicaid coverage and professional guideline adoption. Financially, Aspira reported modest revenue and net income as of Q3 2026, with liquidity challenges noted in filings. The company has pursued capital raises and strategic alternatives to support operations.
Aspira Women's Health Inc. focuses on AI-powered, noninvasive diagnostic tests for gynecologic diseases, primarily ovarian cancer and endometriosis. The company operates a CLIA-certified lab and markets products including Ova1Plus and OvaWatch. It has FDA clearances for key tests and ongoing clinical validation efforts. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. As of September 30, 2026, the company reported limited revenue and net income, with liquidity ratios indicating current liabilities exceed current assets.
Aspira's advanced AI-enabled diagnostic tests address significant unmet needs in gynecologic disease diagnosis, with FDA clearances and clinical validation supporting adoption. The company's proprietary technology and laboratory infrastructure enable ongoing innovation and expansion into larger markets such as endometriosis. Strategic partnerships and efforts to increase Medicaid access and guideline inclusion could broaden market penetration. Successful capital raises and strategic initiatives may support continued product development and commercialization.
Aspira faces challenges including limited current revenue, liquidity constraints, and the termination of a key ARPA-H contract impacting non-dilutive funding for ENDOinform development. The delisting from Nasdaq and trading on OTC markets may affect investor perception and capital access. Regulatory and reimbursement uncertainties, competitive diagnostic technologies, and the need for continued clinical validation pose risks. Delays in product commercialization and market adoption could impact financial performance and operational sustainability.
Aspira's moat derives from its proprietary AI-powered multivariate index assays combining multiple biomarkers, FDA regulatory clearances for its diagnostic tests, and its operation of a CLIA-certified laboratory with multiple accreditations. Its established clinical validation, peer-reviewed publications, and collaborations with academic institutions support product credibility. The company's direct sales force and partnerships with major laboratories provide distribution channels. Additionally, its focus on underserved gynecologic diagnostic markets and efforts to expand Medicaid access and guideline adoption contribute to competitive positioning.
• Liquidity and Funding Risk: The company has disclosed insufficient capital resources to fund operations through the remainder of 2026, necessitating strategic alternatives and capital raising efforts.
• Regulatory and Reimbursement Risk: Aspira's products require FDA clearances and favorable reimbursement decisions; delays or denials could impact commercialization and revenue.
• Product Development Risk: Termination of the ARPA-H contract for ENDOinform development removes a source of non-dilutive funding and may delay product commercialization.
• Market Adoption Risk: Adoption of diagnostic tests depends on physician acceptance, guideline inclusion, and payer coverage, which may be uncertain or slow.
• Trading and Market Perception Risk: Delisting from Nasdaq and trading on OTC markets may affect liquidity, investor confidence, and access to capital.
Business trends: Focus on AI-powered multivariate diagnostic tests for ovarian cancer and endometriosis, with efforts to expand market access and clinical validation.
Execution milestones: Advancement of ENDOinform development, expansion of OvaWatch features, strategic partnerships, and capital raising activities.
Key risks: Liquidity constraints, regulatory and reimbursement uncertainties, product development delays, and market adoption challenges.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Aspira Women's Health Inc. develops and commercializes noninvasive, AI-powered diagnostic tests for gynecologic diseases, focusing initially on ovarian cancer and expanding to other conditions such as endometriosis.
- The company owns and operates Aspira Labs, a CLIA-certified clinical laboratory in Texas, which performs its proprietary tests.
- Key products include the Ova1Plus workflow (combining Ova1 and Overa tests) and OvaWatch, a blood-based risk assessment test for ovarian cancer in women with adnexal masses.
- Ova1 received FDA de novo classification in 2009; Overa received FDA 510(k) clearance in 2016; OvaWatch is commercially available and validated for clinical use.
- Aspira Labs holds multiple accreditations including CLIA certification, state licenses in several states, CMS supplier number, and ISO 13485 certification.
- The company markets its tests through a direct national sales force and channel partnerships with laboratories such as BioReference, ARUP, and Mayo Clinical Laboratories.
- Ova1Plus and OvaWatch revenue are included in the company's reported total revenue for the year ended December 31, 2025.
- Aspira is developing ENDOinform, a multi-marker test for non-invasive diagnosis of endometriosis, with ongoing clinical studies and collaborations.
- The company has published peer-reviewed manuscripts and abstracts supporting the clinical utility of its tests, including OvaWatch's role in surgical referral reduction and longitudinal monitoring.
- Aspira's business model includes efforts to expand access to Medicaid patients and to advocate for adoption of its technology in professional guidelines and legislation.
- The company experienced termination of an ARPA-H contract related to ENDOinform development, impacting non-dilutive funding and potentially delaying commercialization.
- Aspira's capital resources were insufficient to fund operations through the remainder of 2026, leading to pursuit of strategic alternatives and capital raising efforts.
- The company completed a private placement in March 2025 involving convertible promissory notes that were converted into units.
- Aspira's common stock was delisted from Nasdaq in April 2025 and now trades on the OTC QX Best Market under ticker AWHL.
- Financial snapshot as of September 30, 2026: cash and equivalents of $12,000; current assets of $1,849,000; current liabilities of $6,092,000; revenue of $11,000; net income of $339,000; basic and diluted EPS of $0.01; current ratio of 0.3 and cash ratio of 0.
- The company faces risks related to funding, regulatory approvals, market adoption, and the impact of lost non-dilutive funding on product development timelines.
Generated 2026-11-17
- S1 | 2026-04-01 | 10-K
- S2 | 2026-11-16 | 10-Q
- N1 | 2026-11-17 | www.nasdaq.com | Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026 | https://www.nasdaq.com/articles/enanta-pharmaceuticals-reports-financial-results-its-fiscal-fourth-quarter-and-year-ended
- N2 | 2026-11-17 | www.nasdaq.com | PagSeguro Digital Ltd. Reports Net Income of 583,822 Thousand Reais for the Three-Month Period Ended September 30, 2026 | https://www.nasdaq.com/articles/pagseguro-digital-ltd-reports-net-income-583822-thousand-reais-three-month-period-ended
- N3 | 2026-11-17 | www.nasdaq.com | ORIC Pharmaceuticals Reports Third Quarter 2026 Financial Results and Program Updates | https://www.nasdaq.com/articles/oric-pharmaceuticals-reports-third-quarter-2026-financial-results-and-program-updates
- N4 | 2026-11-17 | www.nasdaq.com | RTL Group Q3 Revenue Up 4.8% Organically; Updates 2026 Outlook | https://www.nasdaq.com/articles/rtl-group-q3-revenue-48-organically-updates-2026-outlook
- N5 | 2026-11-17 | www.nasdaq.com | China's NMPA Accepts Akeso's SNDA For Ivonescimab In First-Line Biliary Tract Cancer | https://www.nasdaq.com/articles/chinas-nmpa-accepts-akesos-snda-ivonescimab-first-line-biliary-tract-cancer
- N6 | 2026-11-17 | www.nasdaq.com | Roadzen, Inc. Reports Record Revenue of $17.6 Million and First Positive Adjusted EBITDA Quarter | https://www.nasdaq.com/articles/roadzen-inc-reports-record-revenue-176-million-and-first-positive-adjusted-ebitda-quarter
- N7 | 2026-11-17 | www.nasdaq.com | Lifeloc Technologies, Inc. Reports Third Quarter 2026 Results and Delays SpinDetect Launch to Q4 2027 | https://www.nasdaq.com/articles/lifeloc-technologies-inc-reports-third-quarter-2026-results-and-delays-spindetect-launch
- N8 | 2026-11-17 | www.nasdaq.com | AECOM Reports Fourth Quarter and Full Year Fiscal 2026 Results and Announces 10% Dividend Increase | https://www.nasdaq.com/articles/aecom-reports-fourth-quarter-and-full-year-fiscal-2026-results-and-announces-10-dividend
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


